Tejara Capital Ltd Purchases 132,927 Shares of Certara, Inc. $CERT

Tejara Capital Ltd increased its position in Certara, Inc. (NASDAQ:CERT) by 94.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 273,052 shares of the company’s stock after buying an additional 132,927 shares during the period. Certara comprises approximately 1.7% of Tejara Capital Ltd’s holdings, making the stock its 19th largest position. Tejara Capital Ltd owned 0.17% of Certara worth $3,337,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of CERT. Sector Gamma AS purchased a new stake in Certara during the 3rd quarter valued at approximately $2,818,000. Fort Washington Investment Advisors Inc. OH bought a new position in shares of Certara during the third quarter worth $11,899,000. Intech Investment Management LLC bought a new position in shares of Certara during the second quarter worth $329,000. Versor Investments LP grew its stake in Certara by 104.0% during the second quarter. Versor Investments LP now owns 89,346 shares of the company’s stock valued at $1,045,000 after acquiring an additional 45,546 shares in the last quarter. Finally, Pier 88 Investment Partners LLC bought a new stake in Certara in the 2nd quarter valued at $821,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on CERT. BMO Capital Markets began coverage on shares of Certara in a report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price objective for the company. Leerink Partners upgraded Certara from a “market perform” rating to an “outperform” rating and set a $13.00 target price on the stock in a research report on Tuesday, January 6th. Redburn Partners set a $10.00 price target on Certara in a research note on Friday, November 21st. Stephens cut their price target on Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, December 12th. Finally, Barclays decreased their price objective on Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.58.

Certara Price Performance

NASDAQ:CERT opened at $8.79 on Friday. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of 125.57 and a beta of 1.46. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The business has a 50 day simple moving average of $9.20 and a 200-day simple moving average of $10.38. Certara, Inc. has a 1 year low of $8.02 and a 1 year high of $15.69.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.03. The company had revenue of $104.62 million for the quarter, compared to analyst estimates of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same quarter in the prior year, the firm posted $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Equities analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.